US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Nektar Therapeutics - Common Stock
(NQ:
NKTR
)
39.84
-1.33 (-3.23%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nektar Therapeutics - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
↗
October 01, 2026
Nektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to...
Via
MarketBeat
Nektar (NKTR) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.
Via
The Motley Fool
Topics
Earnings
Nektar Therapeutics Q2 Earnings Call Highlights
↗
August 13, 2026
Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing...
Via
MarketBeat
Topics
Earnings
NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower
↗
May 07, 2026
Via
Chartmill
Topics
Earnings
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call
↗
August 13, 2026
Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For...
Via
Benzinga
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
↗
June 24, 2026
This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
↗
May 23, 2026
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
Via
The Motley Fool
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
↗
May 23, 2026
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Via
The Motley Fool
Topics
Artificial Intelligence
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
↗
May 16, 2026
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
Via
The Motley Fool
Nektar Therapeutics Q1 Earnings Call Highlights
↗
May 08, 2026
Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026...
Via
MarketBeat
Topics
Earnings
Nektar (NKTR) Q1 2026 Earnings Transcript
↗
May 07, 2026
Nektar (NKTR) Q1 2026 Earnings Transcript
Via
The Motley Fool
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
May 05, 2026
From
Pomerantz LLP
Via
GlobeNewswire
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
May 04, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
May 04, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
May 04, 2026
From
Schall Law
Via
GlobeNewswire
NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
April 30, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 30, 2026
From
Schall Law
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
April 30, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 28, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
April 27, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
April 27, 2026
From
Rosen Law Firm
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 27, 2026
From
Schall Law
Via
GlobeNewswire
Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights
April 23, 2026
From
Robbins LLP
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 23, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
April 23, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
April 21, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
April 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 21, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Why Nektar Therapeutics Stock Rocked it Today
↗
April 20, 2026
The biotech reported solid results from its investigational immunology drug in the treatment of a hair-loss disorder.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
